X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA J.B.CHEMICALS AJANTA PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 21.6 18.1 119.4% View Chart
P/BV x 5.1 2.5 207.1% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 AJANTA PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
J.B.CHEMICALS
Mar-16
AJANTA PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,818318 571.5%   
Low Rs1,106200 554.4%   
Sales per share (Unadj.) Rs239.5148.0 161.8%  
Earnings per share (Unadj.) Rs52.819.1 276.6%  
Cash flow per share (Unadj.) Rs59.523.9 248.5%  
Dividends per share (Unadj.) Rs00.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs230.0128.9 178.3%  
Shares outstanding (eoy) m88.7784.82 104.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.11.7 349.1%   
Avg P/E ratio x27.713.6 204.2%  
P/CF ratio (eoy) x24.610.8 227.3%  
Price / Book Value ratio x6.42.0 316.8%  
Dividend payout %02.6 0.0%   
Avg Mkt Cap Rs m129,78221,951 591.2%   
No. of employees `0006.82.7 248.5%   
Total wages/salary Rs m3,7651,841 204.5%   
Avg. sales/employee Rs Th3,128.44,590.9 68.1%   
Avg. wages/employee Rs Th554.0673.4 82.3%   
Avg. net profit/employee Rs Th689.7592.1 116.5%   
INCOME DATA
Net Sales Rs m21,25812,551 169.4%  
Other income Rs m242542 44.6%   
Total revenues Rs m21,49913,093 164.2%   
Gross profit Rs m6,5842,055 320.4%  
Depreciation Rs m596412 144.5%   
Interest Rs m496 4.3%   
Profit before tax Rs m6,2262,088 298.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539469 328.1%   
Profit after tax Rs m4,6861,619 289.5%  
Gross profit margin %31.016.4 189.2%  
Effective tax rate %24.722.5 110.1%   
Net profit margin %22.012.9 170.9%  
BALANCE SHEET DATA
Current assets Rs m12,2367,778 157.3%   
Current liabilities Rs m3,4614,358 79.4%   
Net working cap to sales %41.327.2 151.5%  
Current ratio x3.51.8 198.1%  
Inventory Days Days6055 110.1%  
Debtors Days Days8480 105.6%  
Net fixed assets Rs m11,1405,713 195.0%   
Share capital Rs m177170 104.3%   
"Free" reserves Rs m20,23710,547 191.9%   
Net worth Rs m20,41410,937 186.6%   
Long term debt Rs m100-   
Total assets Rs m24,48615,574 157.2%  
Interest coverage x1,519.422.8 6,658.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.8 107.7%   
Return on assets %19.211.0 174.0%  
Return on equity %23.014.8 155.1%  
Return on capital %30.520.0 152.8%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m11,6676,169 189.1%   
Fx outflow Rs m1,6161,285 125.7%   
Net fx Rs m10,0524,884 205.8%   
CASH FLOW
From Operations Rs m2,8541,397 204.4%  
From Investments Rs m-2,604-320 813.0%  
From Financial Activity Rs m-2-1,196 0.2%  
Net Cashflow Rs m248-102 -242.5%  

Share Holding

Indian Promoters % 73.8 55.4 133.2%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 1.6 3.4 45.7%  
FIIs % 7.6 3.9 194.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 37.0 45.9%  
Shareholders   20,968 30,437 68.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - SANOFI INDIA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS